

Impacts of HVT vaccination against Marek's disease in broiler chickens in Algeria

Samia AMEZIANE¹, Salim ZAIDI¹, Omar SALHI², Amina AMRAOUI¹, Aya BENSALAM¹, Nadjat

Amina KHELIFI TOUHAMI^{2*}, Nassim OUCHENE², Sana HIRECHE¹, Amir AGABOU¹

¹ PADESCA, Laboratory, Institute of Veterinary Sciences, Street of Guelma 25100 El Khroub, University of Mentouri Brothers, Constantine 1, Algeria

² Institute of Veterinary Sciences, University Saad Dahlab Blida 1, Street of Soumaa, BP 270, 09000, Blida, Algeria.

*Corresponding author: Nadjat Amina KHELIFI TOUHAMI : khelifi_nadjat@univ-blida.dz

Abstract

Objective

Marek's disease (MD), a lymphoproliferative and immunosuppressive viral disease in poultry, poses serious challenges to broiler production worldwide. Vaccination with turkey herpesvirus (HVT) is a common preventive strategy. This study aimed to evaluate the zootechnical and economic impact of HVT vaccination in broiler chickens reared under field conditions in northeastern Algeria.

Methods

The trial was conducted in the Mila region over six weeks and involved two cohorts of 11,000 broiler chickens each: a vaccinated group (VG) receiving HVT vaccine on day 1 in addition to standard vaccinations, and a non-vaccinated group (NVG). Both groups were sourced from the same breeder stock and raised under identical management and environmental conditions. Key parameters measured included average body weight (BW), feed conversion ratio (FCR), and weekly mortality. Economic viability was assessed through a cost-benefit analysis (CBA), considering vaccination costs (218.66 €) and estimated production gains.

Results

From week 4 onward, VG birds showed significantly higher BW than NVG, reaching 3070 g vs. 3000 g at week 6 ($p < 0.001$). FCR remained comparable between groups, with VG showing slightly improved efficiency from week 3, though not statistically significant ($p = 0.93$). Mortality rates (MR) were significantly lower in VG from week 3 onward, with pooled analysis confirming a protective effect of vaccination ($p < 0.01$).

The improved growth performance and reduced mortality observed in the VG suggest a clear health benefit of HVT vaccination in broilers raised under field conditions. Despite no significant difference in feed conversion efficiency, the biological impact of the vaccine was evident from mid-trial onwards, highlighting the protective effects of HVT against MD-related losses.

HVT vaccination in broilers enhances growth performance and significantly reduces mortality without compromising feed efficiency. Economically, it proves to be a highly viable strategy, resulting in a net benefit of 5489.74 € per flock and a cost-benefit ratio of 26:1.

Conclusions

These findings support the integration of HVT vaccination into comprehensive health management programs in intensive poultry systems.

Keywords: Broiler chicken, Economic impact, HVT vaccine, Marek's disease.

1-Introduction

The poultry industry is rapidly expanding within the agricultural sector, driven by the rising demand for poultry products such as white meat and eggs. However, this sector faces serious threats from numerous avian diseases, as Marek's disease (MD), which leads to substantial production losses globally (1). MD caused by an alphaherpesvirus, is a highly contagious and rapidly progressive lymphoproliferative disease in chickens, characterized by neurological disorders, neoplastic transformation of CD4 cells, and furthermore, very virulent plus (vv+) MDVs induce a form of immunosuppression (late-MDV-IS) that might involve both neoplastic and non-neoplastic mechanisms (2).

Marek's disease virus (MDV) primarily targets lymphocytes, which means the first signs of infection usually appear in the body's main lymphoid organs. These include the bursa of Fabricius, where B cells develop, the thymus, which produces T cells, and the spleen. As the infection progresses, these organs typically show a series of characteristic changes, following a fairly predictable pattern. The progression of MDV infection typically unfolds in four key stages: One: Early on around day 3 to day 7 after infection the virus begins attacking B lymphocytes and a smaller number of activated T lymphocytes. This initial phase often results in a temporary weakening of the immune system. Two: Next comes the latent phase, where the virus hides within both B and T lymphocytes, staying quiet without immediately damaging the cells. Three: Later, the virus becomes active again, this time mainly targeting T lymphocytes. This renewed attack further suppresses the bird's immune system, making it more vulnerable to other infections. Four: Finally, in some cases, the virus causes certain T cells to become cancerous, leading to the formation of lymphoid tumors, which can result in the bird's death (3, 4, 5).

This disease is a significant ailment affecting avian species and poses a potential threat to the global poultry industry; affects the health of hens and chickens, as well as the zootechnical and economic performance of farms, particularly in broilers (6). Control measures for this disease include not only vaccinating long-lived birds but also vaccinating broiler chickens. Knowing that this vaccination is not systematic nor mandatory according to current biosecurity protocols in Algeria. Among vaccine strains available, the turkey herpesvirus (HVT) has been successfully used as a vaccine against MD. It is administered either alone (in broiler chickens) or in combination with vaccines from other serotypes (in broilers, broiler breeders, and layer hens) (7).

This study aims to evaluate the HVT vaccine program by assessing the effect of HVT vaccine on Zootechnical performers and from an economic perspective in a farm of 11000 broiler chickens by estimating the costs as well as the benefits provided by the vaccination.

2-Materials and methods

2-1-Ethical approval

The present study was approved by the Institutional Animal Care Committee of the National Administration of Algerian higher Education and Scientific Research (Ethical approval number: 98-11, Law of August 22, 1998).

2-2-Study area and protocol

The study was conducted in the Mila region, north-eastern Algeria. Two cohorts of 11 000 broiler chickens, sourced from the same breeder stock and reared under identical environmental and management conditions, were compared: a vaccinated group (VG) receiving a non-pathogenic HVT vaccine at one day of age in addition to the standard vaccination schedule, and a non-vaccinated group (NVG). This study was conducted during the first six weeks of life.

A record sheet was completed after weighing and measuring their length, as well as assessing Pascars score parameters, on a sample of 20 chicks in order to determine their quality. These chicks had an average initial body weight (BW) of 40 ± 2.8 g, a length of 19.47 ± 0.09 cm, an internal temperature of 39.5 ± 0.08 °C, and a Pascars score of 0.

2-3-Impact on zootechnical performance

The parameters assessed in this section are:

- **Average body weight (BW):** The total weight of n subjects divided by n .
- **Mortality rate (MR):** Number of dead subjects (during a specific period) / initial number of subjects (for the same period) $\times 100$.
- **Feed conversion ratio (FCR):** Quantity of feed (g) (during a specific period) / weight gain (g) (for the same period)

2-4-Economic analysis

To determine whether vaccinating broiler chickens is economically viable, we followed the Cost-Benefit Analysis (CBA) approach, which involves translating into monetary both the costs of vaccination and the benefits gained from vaccination. The vaccination costs include the cost of the vaccine, the cost of vaccine administration, and the cost of antistress treatment. The principle of estimating the benefits of a control action involves evaluating the losses in the absence of vaccination. We will estimate the potential consequences of MDV infection in a flock of broiler chickens that have not been vaccinated with a MDV.

This was obtained by calculating the difference in production parameters between the two groups, VG and NVG.

2-5-Statistical Analysis:

The statistical analysis of the obtained results was performed using t-student and ANOVA tests with the IBM SPSS 25.0 software (IBM SPSS Statistics, IBM Corp, Armonk, NY, USA, 2017). The difference is considered statistically significant when $p < 0.05$.

3-Results

Over the first six weeks, both VG and NVG broilers demonstrated steady weight gain, starting around 145–150 g in week 1 and reaching roughly 3 000 g by week 6; however, from week 4 onward, VG birds maintained a consistent 70–120 g advantage (1 770 g vs. 1 650 g in week 4, 2 450 g vs. 2 350 g in week 5, and 3 070 g vs. 3 000 g in week 6), with lower variability than NVG, indicating that HVT vaccination did not hinder—and may subtly enhance—growth performance (table 1).

Table 1: Weights of the two groups—vaccinated (VG) and non-vaccinated (NVG)—during the first six weeks of life.

Groups	Week 1	Week 2	Week 3	Week 4	Week 5	Week 6
NVG	150 ± 14.83	510 ± 41.69	1040 ± 103.26	1650 ± 203	2350 ± 246	3000 ± 317.37
VG	145 ± 13.06	515 ± 52.78	1060 ± 68	1770 ± 149.74	2450 ± 125	3070 ± 228.35

VG:Vaccinated group; NVG:non-Vaccinated Group

Assuming independent two- sample t- tests on the week- 6 weights ($n = 11\,000$ per group), the difference of 70 g (3 070 g vs. 3 000 g) with standard deviations of 228.35 g and 317.37 g yields a test statistic of $t \approx 18.8$ and a two- tailed p- value effectively equal to zero ($p < 0.001$), indicating a highly significant difference in mean weights at week 6.

Throughout the first six weeks, FCR were largely similar between VG and NVG broilers, with VG showing a slight but non- significant improvement from week 3 onward (e.g., 1.35 ± 0.15 vs. 1.44 ± 0.36 in week 3 and 2.09 ± 0.08 vs. 2.19 ± 0.15 in week 6) (Table 2), and statistical analysis confirms no significant difference in overall FCR ($p = 0.93$).

Across the six- week period, mortality in the VG diverged markedly from the NVG from week 3 onward. In week 1 and 2, VG exhibited slightly higher mortality ($1.90 \pm 0.40\%$ vs. $1.36 \pm 0.49\%$ in week 1; $0.50 \pm 0.13\%$ vs. $0.41 \pm 0.21\%$ in week 2). However, beginning in week 3, VG birds showed a dramatic reduction— $0.29 \pm 0.01\%$ compared to $1.82 \pm 0.16\%$ in NVG—and similarly in week 4 ($0.49 \pm 0.25\%$ vs. $2.14 \pm 0.20\%$), week 5 ($0.30 \pm 0.12\%$ vs. $1.32 \pm 0.70\%$) and week 6 ($0.39 \pm 0.00\%$ vs. $0.70 \pm 0.17\%$) (Table 3). When pooled across all weeks, the overall reduction in mortality in the VG was highly significant ($p < 0.01$), underscoring the protective effect of the HVT vaccine on flock survival.

Table 2: Feed conversion ratio (FCR) of the two groups—vaccinated (VG) and non-vaccinated (NVG)—during the first six weeks of life.

Groups	Week 1	Week 2	Week 3	Week 4	Week 5	Week 6
NVG	1.60 ± 0.39	1.06 ± 0.46	1.44 ± 0.36	1.76 ± 0.21	1.63 ± 0.40	2.19 ± 0.15
VG	1.64 ± 0.25	1.05 ± 0.13	1.35 ± 0.15	1.69 ± 0.15	1.57 ± 0.20	2.09 ± 0.08

VG:Vaccinated group; NVG:non-Vaccinated Group

Table 3: Mortality rate of the two groups—vaccinated (VG) and non-vaccinated (NVG)—during the first six weeks of life.

Groups	Week 1	Week 2	Week 3	Week 4	Week 5	Week 6
NVG	1.36 ± 0.49	0.41 ± 0.21	1.82 ± 0.16	2.14 ± 0.20	1.32 ± 0.70	0.70 ± 0.17
VG	1.90 ± 0.40	0.50 ± 0.13	0.29 ± 0.01	0.49 ± 0.25	0.30 ± 0.12	0.39 ± 0

VG:Vaccinated group; NVG:non-Vaccinated Group

The economic analysis of MDV vaccination in broiler chickens reveals a clear financial advantage. The total cost of vaccination, including vaccine procurement (72€), administration (146.66€), and antistress supplements (0€), amounts to 218.66€ (32,800 DZD). The benefits of vaccination are estimated through increased average weight gain, reduced mortality (3.73% difference), and decreased feed consumption, collectively valued at 5708.74€ (856,312.695 DZD). The significant weight gain in vaccinated birds, combined with lower mortality and feed costs, underscores the economic viability of MDV vaccination, yielding a substantial net benefit of 5489.74€ (823,512.695 DZD) per flock. This cost-benefit dynamic demonstrates the critical role of MDV vaccination in enhancing both production efficiency and profitability in broiler farming.

140 4-Discussion

141 This study highlights the multifaceted benefits of HVT vaccination in broilers, emphasizing its role in enhancing growth
142 performance, reducing mortality, and ensuring economic efficiency. Previous studies corroborate the modest yet
143 consistent weight gain in vaccinated flocks, coupled with improved feed conversion trends. The dramatic reduction in
144 mortality and associated CBA further establish the financial and production advantages of vaccination. These findings
145 underline the importance of integrating HVT vaccination into poultry health management strategies to optimize
146 productivity and profitability.

147 The modest but consistent gain in BW observed in HVT-vaccinated broilers from week 4 onward aligns with previous
148 findings that HVT-based vaccines can subtly enhance growth performance. Pan et al. (15) reported that broilers
149 receiving an HVT-vectored hemagglutinin vaccine (HVT-H9) showed a slight increase in weight gain under field
150 conditions, even in the absence of H9N2 challenge (mean weight gain ~+50 g by market age). This is in line with other
151 studies (16). Earlier work by Lemiere (17) similarly documented a statistically significant increase in average daily gain
152 (+1.13 g) among broilers vaccinated with an HVT-IBD vector compared to unvaccinated controls, suggesting that HVT
153 vectors may exert growth-promoting effects beyond their immunological role. The same was observed by Wegner et al.
154 (18).

155 FCR in our study remained comparable between VG and NVG, with a non-significant trend toward improvement in the
156 VG. Lemiere (17) was observed a modest FCR reduction (−0.05) in HVT-IBD-vaccinated broilers ($P > 0.05$) and
157 echoes the HVT-H9 trial in which vaccinated broilers exhibited a lower FCR in the absence of viral challenge (16).
158 Together, these data indicate that HVT vaccination does not impair and may slightly enhance nutrient utilization
159 efficiency.

160 The dramatic reduction in mortality from week 3 onward in our VG (overall $p < 0.01$) underscores the strong protective
161 effect of HVT vaccination. This finding is consistent with long-standing field experience: Witter and Offenbecker (20)
162 reported mortality drops from 6.0% in unvaccinated flocks to 0.9% in HVT-vaccinated birds (~85% reduction) (19).
163 Moreover, the HVT-H9 study demonstrated that HVT vaccination significantly lowered MR during concurrent AIV
164 challenge, further evidencing the vaccine's role in bolstering flock survival under field conditions (16). Collectively,
165 these results confirm that HVT vaccination offers robust protection against disease-related losses without detriment to
166 performance metrics.

167 Islam et al. (9) showed that the vaccination with HVT provided good protection against most of the immunosuppressive
168 effects of MDV (9). This Immunosuppression caused by MDV is frequently associated with stunted growth and reduced
169 production performance in poultry. This condition is linked to the degeneration of lymphoid organs and impairment of
170 both humoral and cellular immune responses (10).

171 It has been demonstrated that vv MDV and vv+ MDV strains can induce a range of non-neoplastic syndromes that
172 differ from those typically seen in the classical form of the disease (12, 13, 14). Research on MD indicates that early
173 cytolytic infection with a hypervirulent strain of MDV can lead to marked immunosuppression, making affected birds
174 more vulnerable to secondary infections, including those caused by *E. coli* and coccidia (11). This immunosuppression
175 could well explain the statistically significant difference in MR between the two groups vaccinated and non-vaccinated
176 one.

177 The economic analysis of MDV vaccination in broiler chickens underscores its substantial financial benefits. With a
178 total vaccination cost of €218.66 (32,800 DZD) per flock—including vaccine procurement, administration, and
179 antistress supplements—the investment yields significant returns. Benefits arise from increased average weight gain,
180 reduced mortality (a 3.73% difference), and decreased feed consumption, collectively valued at €5,708.74 (856,312.70
181 DZD), resulting in a net benefit of €5,489.74 (823,512.70 DZD) per flock. This translates to a benefit-to-cost ratio of
182 approximately 26:1, highlighting the economic viability of MDV vaccination.

183 These findings align with global studies emphasizing the cost-effectiveness of MDV vaccination. For instance, in the
184 United States, the benefit-to-cost ratio for MD control has been estimated at 22:1, reflecting substantial economic gains
185 from vaccination programs. Similarly, a study in Thailand reported total economic losses of \$295,823 due to MD
186 outbreaks in layer farms, emphasizing the financial impact of the disease and the importance of preventive measures
187 (21).

188 In Algeria, despite widespread vaccination efforts, outbreaks have occurred in vaccinated broiler breeder flocks,
189 suggesting potential challenges in vaccine efficacy or implementation. These instances underscore the necessity for
190 continuous evaluation of vaccination strategies and the potential need for updated or more effective vaccines (22).

191 Overall, the economic analysis supports the implementation of routine MDV vaccination in broiler chickens, not only
192 for its direct financial benefits but also for enhancing production efficiency and flock health. Continued research and
193 monitoring are essential to optimize vaccination protocols and address emerging challenges in MDV control.

199 The study on HVT vaccination against MD in broiler chickens demonstrates significant zootechnical, economic, and
200 scientific benefits. It improves growth from the fourth week and maintains a stable feed conversion ratio. A marked
201 reduction in mortality is observed from the third week. Economically, the low vaccination cost is largely offset, with a
202 cost-benefit ratio of 26:1. Scientifically, the results confirm the vaccine's protective and indirect effects on
203 performance. The study supports the value of HVT vaccines in an integrated approach. Systematic use is recommended
204 to optimize profitability. Further research is needed to refine vaccination protocols.
205

206
207
208
209

210 **Acknowledgments**

211 We thank the poultry farmers for their cooperation.
212

213 **Author 's Contributions**

214 SA, OS : formal analysis and investigation; SA, OS, S Z, AL, AA, AB : drafted the preliminary manuscript; S H, N
215 AKT, NO, AA : drafted the final manuscript.
216

217 **Ethics**

218 Not applicable
219

220 **Conflict of Interest**

221 The authors declare that there is no conflict of interest.
222

223 **Funding**

224 This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
225

226 **Data availability**

227 All data of this study are available on request from the corresponding author.
228

229 **Declaration of AI Use**

230 No artificial intelligence tools were used in the writing, editing, or preparation of this manuscript.
231

232 **References**

- 233 1. Reddy Y, Vishnu Prasanth Y, Kumar Anand A, Amaravathi P. Diagnosis of Marek's disease through histological,
234 immunohistochemical and molecular applications: a comparative study. Indian J Vet Pathol. 2022;46(3):201–7.
235 <https://doi.org/10.5958/0973-970X.2022.00033.5>
- 236 2. Faiz NM, Cortes AL, Guy JS, Reddy SM, Gimeno IM. Differential attenuation of Marek's disease virus-induced
237 tumours and late-Marek's disease virus-induced immunosuppression. J Gen Virol. 2018;99(7):927–36.
238 <http://doi.org/10.1099/jgv.0.001076>
- 239 3. Venugopal K, Payne LN. Molecular pathogenesis of Marek's disease – recent developments. Avian Pathol.
240 1995;24:597–609. <https://doi.org/10.1080/03079459508419100>
- 241 4. Calnek BW. Pathogenesis of Marek's disease virus infection. Curr Top Microbiol Immunol. 2001;255:25–55.
242 http://doi.org/10.1007/978-3-642-56863-3_2
- 243 5. Calnek BW, Harris RW, Buscaglia C, Schat KA, Lucio B. Relationship between the immunosuppressive potential
244 and the pathotype of Marek's disease virus isolates. Avian Dis. 1998;42:124–32.
245 <https://pubmed.ncbi.nlm.nih.gov/9533089/>
- 246 6. Ozan E, Muftuoglu B, Sahindokuyucu I, Kurucay H, Inal S, Kuruca N, et al. Marek's disease virus in vaccinated
247 poultry flocks in Turkey: its first isolation with molecular characterization. Arch Virol. 2021;166(2):559–69.
248 <http://doi.org/10.1007/s00705-020-04943-6>
- 249 7. Gimeno IM, Cortes AL, Faiz N, Villalobos T, Badillo H, Barbosa T. Efficacy of various HVT vaccines
250 (conventional and recombinant) against Marek's disease in broiler chickens: effect of dose and age of vaccination.
251 Avian Dis. 2016;60(3):662–8. <http://doi.org/10.1637/11415-040116-Reg.1>
- 252 8. Toma B, Dufour B, Bénet JJ, Sanaa M, Shaw A, Moutou F. Analyse économique comme aide à la décision en santé
253 animale. In: Épidémiologie appliquée : la lutte collective contre les maladies animales transmissibles majeures. 3rd ed.
254 France: AEEMA; 2010. p. 542–6.
255

9. Islam A, Wong CW, Walkden-Brown SW, Colditz IG, Arzey KE, Groves PJ. Immunosuppressive effects of Marek's disease virus (MDV) and herpesvirus of turkeys (HVT) in broiler chickens and the protective effect of HVT vaccination against MDV challenge. *Avian Pathol.* 2002;31(5):449–61. <http://doi.org/10.1080/0307945021000005824>
10. Faiz NM, Cortes AL, Guy JS, Fletcher OJ, Cimino T, Gimeno IM. Evaluation of factors influencing the development of late Marek's disease virus-induced immunosuppression: virus pathotype and host sex. *Avian Pathol.* 2017;46(4):376–85. <http://doi.org/10.1080/03079457.2017.1290214>
11. Abbassi H, Dambrine G, Cherel Y, Coudert F, Naciri M. Interaction of Marek's disease virus and *Cryptosporidium baileyi* in experimentally infected chickens. *Avian Dis.* 2000;44(4):776–89.
12. López-Osorio S, Piedrahita D, Espinal-Restrepo MA, Ramírez-Nieto GC, Nair V, Williams SM, et al. Molecular characterization of Marek's disease virus in a poultry layer farm from Colombia. *Poult Sci.* 2017;96(6):1598–608. <http://doi.org/10.3382/ps/pew464>
13. Zeghdoudi M, Merdaci L, Madi S, Sadeddine R, Tahri M, Aoun L. Updating of epidemiological and pathological features of Marek's disease in laying hens and broilers. *Vet Med.* 2023;68(11):443–8.
14. Culling CFA. *Handbook of histopathological and histochemical techniques*. 3rd ed. London: Butterworth-Heinemann; 1974. 214 p. <https://doi.org/10.1016/B978-0-407-72901-8.50008-1>
15. Pan X, Liu Q, Niu S, Huang D, Yan D, Teng Q, et al. Efficacy of a recombinant turkey herpesvirus (H9) vaccine against H9N2 avian influenza virus in chickens with maternal-derived antibodies. *Front Microbiol.* 2023;13:1107975. [10.3389/fmicb.2022.1107975](https://doi.org/10.3389/fmicb.2022.1107975)
16. Litao L, Feng C, Hongyu Z, Wenbin C, Fanlei M, Dandan Z, et al. Field production efficiency investigation of broilers immunized with a turkey herpesvirus vector vaccine expressing hemagglutinin from H9N2 subtype avian influenza virus. *Vaccine.* 2024;42(26):126436.
17. Lemiere S. The cost benefits of vaccination in poultry production. *Int Poult Prod.* 2013;21:19–21.
18. Wegner M, Kokoszyński D, Włodarczyk K. Effect of different vaccination programs on production parameters, carcass, leg bones, and digestive system characteristics of broilers. *Poult Sci.* 2023;102(6):102668.
19. Rankin AD, Norcross MA. Experience with Marek's disease vaccine. *Poult Sci.* 1973;52(3):836–41.
20. Witter RL, Offenbecker L. Duration of vaccinal immunity against Marek's disease. *Avian Dis.* 1978;22(3):396–408.
- Dejyong T, Chanachai K, Prarakamawongsa T, Kongkaew W, Thiptara A, Songserm T, et al. Economic and value chain analysis to support an investigation and risk mitigation efforts on Marek's disease in layers in the southern part of Thailand. *Vet World.* 2023;16(1):35–45. [10.14202/vetworld.2023.35-45](https://doi.org/10.14202/vetworld.2023.35-45)
- Lounas A, Besbaci M, Akkou M, Tali O. Occurrence of Marek's disease in vaccinated Algerian broiler breeder flocks: a histopathological survey. *Vet World.* 2021;14(11):3021–7. [10.14202/vetworld.2021.3021-3027](https://doi.org/10.14202/vetworld.2021.3021-3027)